High Ferritin Level and Malnutrition Predict High Risk of Infection-Related Hospitalization in Incident Dialysis Patients: A Japanese Prospective Cohort Study

Blood Purification

Volumn 42, Issue 1, 2016, Pages 56-63

  Kato, Sawako ^d   Lindholm, Bengt ^a   Yuzawa, Yukio ^b   Tsuruta, Yoshinari ^c   Nakauchi, Kana ^c   Yasuda, Kaoru ^e   Sugiura, Sachiyo ^e   Morozumi, Kunio ^e   Tsuboi, Naotake ^d   Maruyama, Shoichi ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Meiyo Clinic   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Masuko Memorial Hospital   (Japan)

Author keywords

Dialysis; Ferritin; Infection and malnutrition

Indexed keywords

FERRITIN;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADVERSE EFFECTS; AGED; BLOOD; COMPLICATION; HEMODIALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; COHORT STUDIES; FERRITINS; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INFECTION; JAPAN; KAPLAN-MEIER ESTIMATE; MALNUTRITION; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 84964211739     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000445424     Document Type: Article

References (29)

1. Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758-1764.
2. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.
3. Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, Shlipak MG: The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59: 356-363.
4. Dalrymple LS, Johansen KL, Chertow GM, Cheng SC, Grimes B, Gold EB, Kaysen GA: Infection-related hospitalizations in older patients with ESRD. Am J Kidney Dis 2010; 56: 522-530.
5. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
6. Babitt JL, Lin HY: Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634.
7. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
8. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
9. Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000.
10. Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(suppl 1):S4-S8.
11. Stenvinkel P: C-reactive protein-does it promote vascular disease? Nephrol Dial Transplant 2006; 21: 2718-2720.
12. Miyamoto T, Carrero JJ, Stenvinkel P: Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 662-668.
13. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M: Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study. Nephron Clin Pract 2008; 108:c99-c105.
14. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM: Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579.
15. Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, Kurokawa K, Canaud B, Lameire N, Port FK, Pisoni RL: C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract 2011; 117: c167-c178.
16. Crews DC, Sozio SM, Liu Y, Coresh J, Powe NR: Inflammation and the paradox of racial differences in dialysis survival. J Am Soc Nephrol 2011; 22: 2279-2286.
17. Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, Nanami M, Otaki Y, Nakanishi T: Serum ferritin predicts prognosis in hemodialysis patients: The Nishinomiya study. Clin Exp Nephrol 2010; 14: 349-355.
18. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275.
19. Barton Pai A, Pai MP, Depczynski J, Mc-Quade CR, Mercier RC: Non-transferrinbound iron is associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006; 26: 304-309.
20. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND: Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50-57.
21. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158.
22. Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y: Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012; 16: 819-826.
23. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007; 18: 975-984.
24. Kuo KL, Hung SC, Wei YH, Tarng DC: Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826.
25. Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, Mayer G, Weiss G: Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 2011; 26: 977-987.
26. Meuwese CL, Carrero JJ, Stenvinkel P: Recent insights in inflammation-associated wasting in patients with chronic kidney disease. Contrib Nephrol 2011; 171: 120-126.
27. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35(6 suppl 2):S1-S140.
28. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K: Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 2013; 28: 1936-1945.
29. Mitrache C, Passweg JR, Libura J, Petrikkos L, Seiler WO, Gratwohl A, Stahelin HB, Tichelli A: Anemia: an indicator for malnutrition in the elderly. Ann Hematol 2001; 80: 295-298.